Romidepsin (FK228, Depsipeptide)

目录号:S3020 别名: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。

规格 价格 库存 购买数量  
RMB 1285.83 现货
RMB 3910.79 现货
RMB 5710.89 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的3个实验数据:

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。
特性 Romidepsin对I型HDAC的抑制作用明显强于对II型HDAC的抑制。
靶点
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外研究

Romidepsin抑制NSCLC细胞系生长,IC50范围从1.3 ng/mL到4.9 ng/mL。 Romidepsin可以降低Erlotinib对NSCLC细胞系的IC50值, 增加NSCLC细胞系对Erlotinib的敏感性[1]。Romidepsin处理72小时可以抑制6/6 人 NB 肿瘤细胞系的生长,而 NIH3T3细胞系并不受影响。 Romidepsin对于单拷贝或N-myc 多拷贝的NB细胞系以及含有正常或突变的p53 和含有Alk突变体的细胞系都有选择性的细胞毒性,这种毒性具有剂量依赖的特性。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 MlfRR4VtdCCYaXHibYxqfHliQYPzZZk> M{DmbVIvPS1zNTDuUS=> Mn\HO|IhcA>? NEexXFhqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MoCwNlU4QTB7MEe=
U2932  MnfwR4VtdCCYaXHibYxqfHliQYPzZZk> NFjFW2QzNjVvMUWgcm0> MVG3NkBp Moq4bY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MoTUNlU4QTB7MEe=
OCI-LY7 M1HKSWNmdGxiVnnhZoltcXS7IFHzd4F6 NV;PPIk3Oi53LUG1JI5O NHTSUnk4OiCq MUfpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MkPLNlU4QTB7MEe=
Farage MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYmyMlUuOTVibl2= M4TnXFczKGh? MX;pcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh M4\aNFI2PzlyOUC3
LY7/EBV M2fSVGNmdGxiVnnhZoltcXS7IFHzd4F6 NWjYNZlHOi53LUG1JI5O MWi3NkBp MYjpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MWKyOVc6ODlyNx?=
U2932/EBV NHTHTpNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVOyMlUuOTVibl2= NF\neIo4OiCq NFnxeWFqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MU[yOVc6ODlyNx?=
HCT116 NFLnUpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2izSlUuPTByMDDuUS=> M32wS|I1KGh? NVfBXFN4TE2VTx?= NHrJWZVqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> M1rsSlI2PDl{NUG1
ACH-2 M{DkNWZ2dmO2aX;uJGF{e2G7 M2\ufFEuQSCwTR?= M4HRTlI1KGh? NUnYboE{cW6mdXPld{BJUVZvMTDFcpYh\XiycnXzd4lwdg>? NUHsTIo4OjVzNEm0Olc>
MCF-10A MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M132[GlEPTB;MD6xO:KyOC5yMTDuUS=> NETiOZozPDl3NEi1Oi=>
MCF-7 NHfEPG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG5TWM2OD1zLkGwxtExNjJyIH7N MkXrNlQ6PTR6NU[=
SK-BR-3 M1Gzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnR[5FMUUN3ME2xMlAxyrFyLkO1JI5O M2nQbVI1QTV2OEW2
MDA-MB-231 MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TBUmlEPTB;MD62POKyOC5zNDDuUS=> NVvYT2pDOjR7NUS4OVY>
PC3 M3S5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\BZ2lEPTB;MT62OeKyOC5|NTDuUS=> MorYNlQ6PTR6NU[=
HCT116 NFKyXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3NTWM2OD1zLkCwxtExNjByIH7N MYGyOFk2PDh3Nh?=
HCT116-p21-/- NFTwTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7nTWM2OD1zLkK2xtExNjN5IH7N MUOyOFk2PDh3Nh?=
S1 Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTdwNkhCtVAvOjlibl2= NWHSSldGOjR7NUS4OVY>
SW620 M3;Jdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwOURCtVAvOjlibl2= MYqyOFk2PDh3Nh?=
LOX-IMVI NX7LeGw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzJbnZKSzVyPUCuPFfDuTBwMEOgcm0> M1ztSlI1QTV2OEW2
UACC-62 NFH0OIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTwUpUzUUN3ME2wMlU3yrFyLkG2JI5O M3PJNVI1QTV2OEW2
MDA-MB-435 NVLSdYp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHSTWM2OD1yLkmwxtExNjB4IH7N M3fJWVI1QTV2OEW2
SF-295 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwOElCtVAvOTVibl2= NGDCbZkzPDl3NEi1Oi=>
A549 M1TEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e1fWlEPTB;MT6yOuKyOC5{NDDuUS=> NFrkfYEzPDl3NEi1Oi=>
H460 NH3tO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjkcGJJUUN3ME2yMlU5yrFyLkiwJI5O NGrXXI8zPDl3NEi1Oi=>
EKVX MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrucXdKSzVyPUGuN|PDuTBwM{Sgcm0> MknpNlQ6PTR6NU[=
H146 NX:xfZczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFX4bnVKSzVyPUCuNlLDuTBwMEegcm0> NUGx[JZyOjR7NUS4OVY>
H526 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMUZCtVAvODNibl2= MVmyOFk2PDh3Nh?=
HuT-78 MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW4fZZPUUN3ME2xMlc{yrFyLkS0JI5O MX6yOFk2PDh3Nh?=
HA M3HFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEKxPXkxNjZ{NT2xNI5O MUm0PEBp NXv0eG5VcW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? M3[zfFI1PzdzNUGw
MS-275 NV30bZJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXSe5RZOC54MkWtNVBvVQ>? NVTqPIJIPDhiaB?= MkXwbY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> MX:yOFc4OTVzMB?=
CD4 T NHTLTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zIclQ5KGh? NU[4dWRPTUN3ME20MlXDuTFwMDDuUS=> NIrhOYEzPDd{MkS1OC=>
CD4 T M1zadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvje3g1QCCq MkHsR2M2OD1zMEhCtVEzPiCwTR?= NXjOe5lTOjR5MkK0OVQ>
CD4+ T M{fZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlK4SWM2OD1|IH7N M4P3d|I1PDl3MUC1
A549 M{fIZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfKO3YyOOLCk{GwNOKhdk1? NFn4OW0zPC9|Nj:0PEBp NFHBWHRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NF;pcJUzPDR6NUe5PS=>
JJN3 NGjENZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLie5AzPC92ODDo MYjFR|UxRDIkgJnuUVshPDkkgJno NETjelAzPDB|MEG1NC=>
OPM-2 M3fTZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmyOE81QCCq MlXYSWM2OHN;MfMAjY5OQyB2OPMAjYg> MnWwNlQxOzBzNUC=
RPMI-8226 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nTSVI1NzR6IHi= M3fkXWVEPTC|PUGuPQKBkW6POzC0PQKBkWh? MWOyOFA{ODF3MB?=
U266 MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnlclUzPC92ODDo Ml72SWM2OHN;MUFihKlvVTtiNElihKlp NVfUeXRCOjRyM{CxOVA>
CA46 MkX2RZBweHSxc3nzJGF{e2G7 MVu2JIg> NWi2b4IzcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= MmDhNlM6PjZzNkS=
DG75 MkLzRZBweHSxc3nzJGF{e2G7 M2CybVYhcA>? NGHiTWVqdmS3Y3XzJI5wKGGyb4D0c5Nqew>? Mm\ENlM6PjZzNkS=
Ramos MUTBdI9xfG:|aYOgRZN{[Xl? MnGyOkBp MmPmbY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nz MoTYNlM6PjZzNkS=
ST486 Mkj6RZBweHSxc3nzJGF{e2G7 Mo\pOkBp NIW0NolqdmS3Y3XzJIV5fGWwc3n2[UBieG:ydH;zbZM> NVPUZ4NIOjN7Nk[xOlQ>
HuT78 MYrBdI9xfG:|aYOgRZN{[Xl? NIj1UJEyNzFyL{GwNEBvVQ>? NFWzWI01QCCq NH3DTo5qdmS3Y3XzJIFxd3C2b4Ppd{BifCBzIH7N M3HnVVI{PTN{N{Oy
DpVp35 NYXwXJpwSXCxcITvd4l{KEG|c3H5 MlLPNU8yOC9zMECgcm0> NYCzboFNPDhiaB?= M{O5dIlv\HWlZYOgZox2dnRiYYDvdJRwe2m| M4XXUlI{PTN{N{Oy
DpVp50 NHnCbIxCeG:ydH;zbZMhSXO|YYm= M4XBTlEwOTBxMUCwJI5O Ml7DOFghcA>? NV7IdoNxcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NHzpT|IzOzV|MkezNi=>
DpP75  M2ixfmFxd3C2b4Ppd{BCe3OjeR?= NFrvSYQyNzFyL{GwNEBvVQ>? NHjWPIw1QCCq M4nRfolv\HWlZYOgZox2dnRiYYDvdJRwe2m| MkKyNlM2OzJ5M{K=
SKOV-3 MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDoVYJSOeLCk{Kwcm0> MWq3NkBp M3TUdmROW09? NIfwNppz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? MUCyN|AyODN2OB?=
Brca1 WT Mkn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki1NgKBmzJybl2= MlXpO|IhcA>? Mo\2SG1UVw>? MljFdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> Mkj5NlMxOTB|NEi=
Brca1 Null NH:5bldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vhV|HjiJN{MH7N NYf4S21wPzJiaB?= M3jNZWROW09? MX\y[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> MViyN|AyODN2OB?=
OVCAR-8  MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmx5qCUOjCwTR?= M2TjRlczKGh? NVLoO5lTTE2VTx?= NG\IcVJz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NELNNXAzOzBzMEO0PC=>
NCI/ADR-RES NUDQTZhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Tj[lHjiJN{MH7N NELq[4E4OiCq M4TuXmROW09? NI\WdGJz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? M33jOFI{ODFyM{S4
HCT116 NFHMSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\Ue|Uhdk1vNUCg{txO NX\ZV5g6OjRiaB?= NUG0SpVrTE2VTx?= M3vzVolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MV:yNlkzPDl3OB?=
RKO NX3ST3p7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXNcZZ5PSCwTT21NEDPxE1? MUOyOEBp NH;ERVhFVVOR MVzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MYOyNlkzPDl3OB?=
CO115 M4nWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTOS402KG6PLUWwJO69VQ>? NIXmOXEzPCCq M4LsdWROW09? NITEZ21qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? M3vvSFIzQTJ2OUW4
HFS NH7qZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYm1JI5O NIHuZnQzPC92OD:3NkBp M2i4[IlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> Mnv5NlIyODZ{OEK=
LNCaP M3[wNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zCeFUhdk1? M1jCfVI1NzR6L{eyJIg> NGjsc2JqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 M{fZV|IzOTB4Mkiy
A549 NWPhfJJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHsSHE2KG6P M4ewZVI1NzR6L{eyJIg> MYLpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 MoK2NlIyODZ{OEK=
697  NGj0S4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TWOmlEPTEkgJm95qCKOi53wrDuUS=> MoXMNlE2Ozh{MU[=
697-R NUnGTZk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTxVIVKSzVy4pEJQgKBkThwNtMgcm3DqA>? MXOyNVU{QDJzNh?=
HUT78 MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoeyTWM2OD1zIH7N M3rhUVIyOTl6NUS1
THJ-16T M2XiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrqNUBvVQ>? MX[yOEBp NGnleY1qdmirYnn0d{Bk\WyuIHfyc5d1cA>? M3Tj[VIxQDFyNU[4
HCT116 NWrNUIx1TnWwY4Tpc44hSXO|YYm= MmjBNlAhdk1? MYi4JIg> NWfQfFVRdW:mdXzheIV{KHS{YX7zZ5JqeHRibHX2[Yx{KG[xcjDoeY5lemWmczDv[kBo\W6nczDpckBmcXSqZYKg[Ilz\WO2aX;u NVHCdo1EOjB5M{m0OVQ>
B104  M335WWZ2dmO2aX;uJGF{e2G7 MVeyJI5O NY\td5lCOjRxNEivO|IhcA>? Mm\hbY5kemWjc3XzJJRp\SC|dYLmZYNmKGW6cILld5Nqd25ib3[gR2QzOMLi MV[yNFY5PjVyNR?=
HL-60  M{nOfGN6fG:2b4jpZ4l1gSCDc4PhfS=> NHHFNlYyNTVyMDDuUS=> MXGyOEBp MYPpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MorFNlA3OjRzNkO=
HP100 M3fzRmN6fG:2b4jpZ4l1gSCDc4PhfS=> MXqxMVUxOCCwTR?= MXqyOEBp Mmi1bY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NXrjNY9OOjB4MkSxOlM>
HL-60  M3zSS2Z2dmO2aX;uJGF{e2G7 NYeyOJZPOTBibl2= MnOyOE83NzF4IHi= Moe0bY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq M3HvN|IxPjJ2MU[z
HP100 MkixSpVv[3Srb36gRZN{[Xl? MmHINVAhdk1? MX60M|YwOTZiaB?= MVvpcoR2[2W|IITo[UBo\W6ncnH0bY9vKG:oIHj5[JJw\2WwIIDldo95cWSnIH\yc40hPGh? NWK5bVR3OjB4MkSxOlM>
HL-60  NVHVZ3V3TnWwY4Tpc44hSXO|YYm= M3nUR|ExNTVyMDDuUS=> M4XPfVQhcA>? NVjCWI1l\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg NXe0[|RPOjB4MkSxOlM>
HP100 M2PsbWZ2dmO2aX;uJGF{e2G7 NELMXosyOC13MECgcm0> NEDoS3o1KGh? NHrYbYtl\WO{ZXHz[ZMhfGinIHjpd5RwdmViZHXhZ4V1gWyjc3WgLGhFSUNrIHHjeIl3cXS7wrC= MnjHNlA3OjRzNkO=
11z MUPLbY5ie2ViQYPzZZk> NGfleng{NTFyMDDuUS=> NGT0WZFz\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?= NWHufpMzOjB4MEWxOFQ>
SKOV-3 MoT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnrc3ZqPC96L{G2JI5O NIHyeJA1QCCq NGewVGVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? M3PWelIxPDB2NU[0
OVCAR-3 NF7J[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{S5fVQwQC9zNjDuUS=> NX3MNlBOPDhiaB?= Mn3ybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MnSwNlA1ODR3NkS=
HBL-2 NG\OXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDwdJkzNTFyIH7N NFe4OJYzPCCq NGrkeZZKSzVyPUSuN{BvVQ>? NWnRO|V7OjByNkiwPFA>
Jeko-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ex[FIuPTBibl2= Ml;nNlQhcA>? M3\pcGlEPTB;MUGgcm0> MonrNlAxPjhyOEC=
Granta-519 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS4[4piPS12MDDuUS=> MknaNlQhcA>? Mn;qTWM2OD13OD61JI5O NUHuRoZROjByNkiwPFA>
L1236 M3XOcWN6fG:2b4jpZ4l1gSCDc4PhfS=> MUexJI5ONTFyMDFOwG0> NGXhfYo1QCCq NHLtfZlGSzVyPUCuNFch|ryP MnPVNVkzOzN2N{C=
L428 MYnDfZRwfG:6aXPpeJkhSXO|YYm= MWCxJI5ONTFyMDFOwG0> Mn\YOFghcA>? M2\X[WVEPTB;MD60N{DPxE1? NH;BWGUyQTJ|M{S3NC=>
KM-H2 NI\Nb2VEgXSxdH;4bYNqfHliQYPzZZk> M3vQXlEhdk1vMUCwJO69VQ>? NHPSdYI1QCCq NWjofpNtTUN3ME2wMlU5KM7:TR?= MWGxPVI{OzR5MB?=
L540Cy NXrZemp{S3m2b4TvfIlkcXS7IFHzd4F6 MnrxNUBvVS1zMECg{txO MoX4OFghcA>? NHftcm1GSzVyPUCuNVYh|ryP M{\w[|E6OjN|NEew
G401 NWrjXGtHTnWwY4Tpc44hSXO|YYm= MmfvNVAhdk1? M1q5[lI1NzR6L{eyJIg> NYjnemRiTE2VTx?= MnLnbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u NV3MTm9MOTl{MkG1PFY>
STM91-01 NXWxTFFvTnWwY4Tpc44hSXO|YYm= M3\4O|ExKG6P MUGyOE81QC95MjDo M1PB[GROW09? MoHGbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u M37RRVE6OjJzNUi2
SJSC  NH3WPZJHfW6ldHnvckBCe3OjeR?= NVvvbZJoOTBibl2= MlfXNlQwPDhxN{KgbC=> Mmq2SG1UVw>? NV3B[3pUcW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v MorTNVkzOjF3OE[=
BT16  M3PIUmZ2dmO2aX;uJGF{e2G7 MX2xNEBvVQ>? MmfwNlQwPDhxN{KgbC=> MXvEUXNQ M4rmc4lv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> Mkn5NVkzOjF3OE[=
NCI-H1299 Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTRwNtMxNE4zKG6pL33s M1LvR|E6OTd7OEmw
NCI-2882 M17ZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS0XYNKSzVyPUGuOuKyOC5yNDDu[{9udA>? MmXoNVkyPzl6OUC=
HCC95 M3zGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJwNdMxNE4xPSCwZz;tcC=> NVvwSppiOTlzN{m4PVA>
NCI-H23 MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJwOdMxNE4zKG6pL33s NWj4WmJvOTlzN{m4PVA>
NCI-H157 MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTFwNtMxNE4xOiCwZz;tcC=> NH:zSWEyQTF5OUi5NC=>
NCI-H460 M4XIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJwMdMxNE4xPyCwZz;tcC=> MkPLNVkyPzl6OUC=
NCI-H1975 M4[zVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFwM9MxNE4xPCCwZz;tcC=> NFXS[YYyQTF5OUi5NC=>
NCI-H820 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJwNNMxNE4yKG6pL33s MYKxPVE4QTh7MB?=
NCI-H1650 M3;ER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\u[nNKSzVyPUSuPeKyOC5|IH7nM41t M1y2clE6OTd7OEmw
DTC1 MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoC1TWM2OD1yLkWxJI5O NG\lcW0yQDV4NkK0Oi=>
KAO NVvlR5NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3e5[WlEPTB;MD65NUBvVQ>? MmDtNVg2PjZ{NE[=
SU-CCS-1 NX\MdWJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Po[WlEPTB;MD64PUBvVQ>? MUmxPFU3PjJ2Nh?=
SYO-1 NFLZXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXOc2tKSzVyPUCuOlchdk1? MWmxPFU3PjJ2Nh?=
FUJI MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfMSnQ4UUN3ME2xMlMyKG6P NWrP[o1jOTh3Nk[yOFY>
SKNMC M1HybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXqTXo1UUN3ME2xMlE4KG6P NYjOTGRYOTh3Nk[yOFY>
402-91 NUXsOHpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjEPJFKSzVyPUGuNlYhdk1? NVXVe5Z2OTh3Nk[yOFY>
1765-92 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjINWNGUUN3ME2xMlc4KG6P MoTCNVg2PjZ{NE[=
JN-DSRCT-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXwTWM2OD1zLkK1JI5O MoruNVg2PjZ{NE[=
NMS-2PC M3\QS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjOUGNwUUN3ME2wMlgyKG6P NV23W5JTOTh3Nk[yOFY>
HL60 MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrVTWM2OD1zLki2JI5O M3PXNVE5PTZ4MkS2
A549 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1myb2lEPTB;Mz6yOEBvVQ>? M1TYU|E5PTZ4MkS2
SW480 NH3qZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nPb2lEPTB;Mj62PUBvVQ>? NGXscVcyQDV4NkK0Oi=>
MCF7 M2GydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTNwNUWgcm0> NGTa[4gyQDV4NkK0Oi=>
PC-3 NFzhXXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfHdWVUUUN3ME2yMlUyKG6P M3HYfFE5PTZ4MkS2
MMRU NEHP[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfVc3lKSzVyPUKuOVchdk1? NFfhXYkyQDV4NkK0Oi=>
Hs68 MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDDbYFmUUN3ME2+NVAhdk1? NF7NcosyQDV4NkK0Oi=>
hMSC-001F MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPHc4RKSzVyPU6xNEBvVQ>? NHm4ZXYyQDV4NkK0Oi=>

... Click to View More Cell Line Experimental Data

体内研究 与PBS处理的对照组相比,单独使用Erlotinib 和 Romidepsin分别可以对NCI-H1299细胞系的异种移植生长抑制到72% 和 43% ,但是并不具有明显的统计学意义。只有当两种药物联用的时候才会对其生长造成明显的抑制作用,此时生长被抑制到28% [1]。在免疫功能低下的小鼠中,Romidepsin 会抑制皮下NB 异种移植的生长,这种抑制作用具有剂量依赖的特性 。此外, 在NB病人的肿瘤组织中Romidepsin 会诱导某些基因的表达,如 p21 和p75 以及NTRK (TrkA) [2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
细胞实验:[3]
+ 展开
  • Cell lines: NCI-H1975, NCI-H157, NCI-2882, NCI-H460 和 HCC95 细胞系
  • Concentrations: 1 ng/mL
  • Incubation Time: 72 小时
  • Method: 使用MTS法分析药物敏感性。在96孔平板中每孔接种2×103个细胞(包括NCI-H1975, NCI-H157, NCI-2882, NCI-H460和HCC95) 。24小时后, 在存在或者缺少1 ng/mL Romidepsin的条件下将细胞与不同浓度 (0.01 µM - 250 µM) 的Erlotinib 37°C 孵育72 小时。 MTS 溶液加到每个孔中37°C孵育1小时。利用分光光度计测量490 nm 处的光密度值。每种药物浓度的实验都设置8个复孔并重复两次。基于细胞生存曲线的吸光度值计算药物的半抑制浓度 (IC50) 。
    (Only for Reference)
动物实验:[5]
+ 展开
  • Animal Models: 携带NCI-H1299 细胞的 BALB/c无胸腺裸小鼠
  • Formulation: 用PBS配制
  • Dosages: 1.2 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次加入纯溶剂:
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 540.7
化学式

C24H36N4O6S2

CAS号 128517-07-7
稳定性 powder
别名 FR 901228, NSC 630176

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)供应商 | 采购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)价格 | Romidepsin (FK228, Depsipeptide)生产 | 订购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID